Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations
NCT04195555 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- July 20, 2020
- Completion date
- May 9, 2027
- Enrollment
- 3 (actual)
- Sites
- 174
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent ependymoma, recurrent ewing sarcoma, recurrent hepatoblastoma, recurrent langerhans cell histiocytosis, recurrent malignant germ cell tumor, recurrent malignant glioma, recurrent malignant solid neoplasm, recurrent medulloblastoma, recurrent neuroblastoma, recurrent non-hodgkin lymphoma, recurrent osteosarcoma, recurrent peripheral primitive neuroectodermal tumor, recurrent rhabdoid tumor, recurrent rhabdomyosarcoma, recurrent soft tissue sarcoma, recurrent who grade 2 glioma, refractory ependymoma, refractory ewing sarcoma, refractory hepatoblastoma, refractory langerhans cell histiocytosis, refractory malignant germ cell tumor, refractory malignant glioma, refractory malignant solid neoplasm, refractory medulloblastoma, refractory neuroblastoma, refractory non-hodgkin lymphoma, refractory osteosarcoma, refractory peripheral primitive neuroectodermal tumor, refractory rhabdoid tumor, refractory rhabdomyosarcoma, refractory soft tissue sarcoma, refractory who grade 2 glioma, wilms tumor